Products for Research Use Only
RegisterLogin

OR-1855

CAT: 0804-HY-W050000-01Size: 50 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-W050000-01Size:50 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
OR-1855, an active metabolite of Levosimendan , has effect on myometrial contractility. OR-1855 exerts anti-inflammatory effects by inhibiting IL-1β-induced ROS formation and NAD (P) H oxidase-dependent superoxide radical generation in HUVECs. OR-1855 inhibits IL-1β-induced phosphorylation p38 MAPK, ERK1/2, c-Jun and JNK in HUVECs. OR-1855 can be used for the study of inflammation[1][2][3].
CAS Number
101328-85-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Drug Metabolite; ERK; p38 MAPK; Reactive Oxygen Species (ROS)
Type
Reference compound
Related Pathways
Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/or-1855.html
Concentration
10mM
Purity
99.78
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1C[C@@H](C)C(C2=CC=C(N)C=C2)=NN1
Molecular Formula
C11H13N3O
Molecular Weight
203.25
Precautions
H302, H315, H319, H335
References & Citations
[1]Banfor PN, et al. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol. 2008 Jan;294 (1) :H238-48.|[2]Mark P. Hehir, et al. 487: OR-1855, a levosimendan metabolite with an effect on human myometrial contractility.December 2009Volume 201, Issue 6, Supplement, Pages S182-S183.|[3]Kipka H, et al. The Effects of the Levosimendan Metabolites OR-1855 and OR-1896 on Endothelial Pro-Inflammatory Responses. Biomedicines. 2023 Mar 16;11 (3) :918.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-145733-01DI-1859
HY-150737-01MI-1851
HY-135892-01GNE-1858
HY-106247AG-1859
HY-136181A-01YNT-185
HY-179143EGFR-IN-185
HY-15611-01KPT-185
HY-157487Anticancer agent 185
HY-136181-01YNT-185 (dihydrochloride)
HY-171893CRBN ligand-185

Alternative Products

CatalogName
GTR19204256-01OR-1855
TL304872VDVL1 Human shRNA Lentiviral Particle (Locus ID 1855)
TG304872DVL1 Human shRNA Plasmid Kit (Locus ID 1855)
SR301305DVL1 Human siRNA Oligo Duplex (Locus ID 1855)

Popular Products